Media.Player

Cloned tumor specific MHC-unrestricted T Cell Receptor for gene therapy/immunotherapy of over 85% of human tumors

Detailed Technology Description

None

*Abstract

MUC1 glycoprotein is overexpressed on the surface of a variety of epithelial tumors and has been under investigation as a target for immunotherapy. Transduction of bone marrow cells with tumor-specific TCR represents a potentially efficacious gene therapy/immunotherapy approach. MUC1-specific MHC-unrestricted TCR will make this treatment applicable to all cancer patients with MUC1 tumors, regardless of their HLA type.This invention pertains to the treatment or prevention of cancer in humans involving transfer of (a) an isolated population of cells, or (b) cells transduced with a nucleic acid encoding a receptor, into a human in need of treatment or prophylaxis for cancer. The present invention also pertains to a method of activating a signaling pathway. The invention provides a method of activating a signaling pathway in a cell. The method comprises transducing the cell with at least one nucleic acid that encodes a receptor so that the receptor is expressed and displayed on the surface of the cell. The encoded receptor is capable of binding to a MUCl antigen without requiring the MUCl antigen to be presented in the context of a major histocompatibility complex (MHC). The receptor either interacts with a signaling molecule, or comprises a signaling domain, such that when the receptor is contacted with a cell having the MUCl tumor antigen on its surface, the signaling pathway is activated.

*Principal Investigator

Name: Nehad Alajez

Department: Med-Immunology

Name: Mark Alter

Department: Department of Child and Adolescent Psychiatry

Name: Olivera Finn, Professor

Department: Med-Immunology

Name: Jan Schmielau

Department:

Country/Region

USA